Abstract
N-oxide-containing compounds have been developed as prodrugs that are selectively bioactivated in the hypoxic cells in tumors. This selectivity is based on the net reduction of the N-oxide moiety in the absence of oxygen, in a one or two-electron process, by reductive enzymes. A wide range of N-oxides have been studied and some of them are currently in clinical use. This review covers the principal families of compounds under study and in clinical trials.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Antioxidants / chemical synthesis
-
Antioxidants / chemistry
-
Antioxidants / pharmacology
-
Cell Hypoxia / drug effects*
-
Cytotoxins / chemical synthesis*
-
Cytotoxins / chemistry
-
Cytotoxins / pharmacology
-
Drug Design
-
Humans
-
Models, Molecular
-
Molecular Conformation
-
Neoplasms / pathology
-
Nitrogen Oxides / chemical synthesis*
-
Nitrogen Oxides / pharmacology
-
Structure-Activity Relationship
Substances
-
Antioxidants
-
Cytotoxins
-
Nitrogen Oxides